Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
about
Second malignant neoplasms and cardiovascular disease following radiotherapy.Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 raReduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.Ethnic differences in chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study.Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.Busulfan in hematopoietic stem cell transplantationReduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a rAutologous hematopoietic stem cell transplantation in lymphoma patients is associated with a decrease in the double strand break repair capacity of peripheral blood lymphocytesTherapy-related acute myeloid leukemia in patients with lymphoma: A report of four cases and review of the literature.Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?Autologous peripheral blood hematopoietic cell transplantation in dogs with T-cell lymphoma.Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma.Secondary Malignant Neoplasms Following Haematopoietic Stem Cell Transplantation in ChildhoodReduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients.Autologous transplant of follicular lymphoma in the era of rituximab.Transplantation for non-Hodgkin lymphoma.The role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings.Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors.Mechanisms of oncogenic chromosomal translocations.Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22 466 survivors in Israel with 30 years of follow-up.PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCERPhase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma.Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study.The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls.Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma.Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study.Attenuator design for organs at risk in total body irradiation using a translation technique.Positive HIV ELISA test, autoimmune hemolytic anemia, and generalized lymphadenopathy: a unifying diagnosis.Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis
P2860
Q26864522-3D34906C-2CC1-41DF-B8FC-B5B4F85CB781Q30248407-EDE620F1-6674-4041-8B87-7F8F1D37C8CAQ30481608-A83BF542-E537-4342-9462-B16F93AE8CB9Q33680218-61B9E9B4-3454-4DD2-990B-140C3DCE63F7Q34091836-3EDF7015-DEE8-4C99-B7B5-86D0E4CA9E20Q34102941-46FE9341-E0CB-4AFE-B6BA-8A15EEABD20BQ34668052-D8BD87D6-7857-4B20-89CF-5E4DFF8D7214Q35100217-B09E646A-119F-48AC-822C-E9A2326D58F3Q35136616-83E55B9B-DDDC-488D-9E56-4F7D3F410158Q35638755-54E5F941-F183-4F3E-8CEA-2F23483D8453Q36282672-0D29EC28-3514-4130-967A-968CE7535789Q36335336-5AE1E4DB-97C4-4C8D-BB74-C88DFC729C5BQ36672691-9F629DB9-1166-4798-9E61-D1EDB1E48711Q36873348-F39F5187-E082-47B4-8167-430D0D36216AQ36950052-B16A615C-4279-4626-B665-3C7FEDA3FE36Q37055896-1F2AD3AF-398E-4382-A7B5-EFD19FBD6990Q37082736-58228D40-E9AB-4EF6-9427-9C7C3A3F0477Q37548821-19C54F1B-06FF-43B2-84EA-E75FB875E6CBQ37742624-D4A598CC-6952-42DB-B7C3-29604264231DQ37810079-FF11697F-6425-4A68-9C28-121CB2526459Q37824456-B1CE2B22-2BAE-4658-B255-35F30B035F5EQ38045706-CFE9BDF7-49DF-4927-83B1-2F55BCC9E4BFQ38093037-B805B87D-0DC7-47E8-986A-7A52C412E3ECQ38188051-D5296633-23F6-4EC2-B510-D34E4B48C305Q39353147-F96286AA-DE19-485E-A9B6-4963C9A25164Q39727079-B1B69184-584B-4B9A-B7AC-99C3E28384B1Q40843669-52CEC6B4-7425-4279-990E-AF3F48400D6EQ43135381-41F2990C-6B77-4C0B-B63A-D73C91EB5DADQ44366982-F6D2522B-E265-4C89-B68A-90D8DC954AAFQ44595367-EEDA2591-1B91-4098-8139-0526EE384373Q44676921-8E9C5503-EB86-40B9-9882-69FEBD6DABAAQ44729105-986C57FA-F17D-4AEB-979E-BD53A63FBC09Q46060624-EBEFD435-9E08-4E93-8888-463EF95D6C27Q47593550-D33073D2-3E03-4965-B561-51D1D1DBD2B1Q47629608-FE502B90-003A-4598-A8CA-72A9754C4C47Q53243781-5ADED46A-4529-4EB3-893E-E5D65DD5C7B2Q58553753-9EABB227-C756-446C-A7B4-87AC6BBCF782
P2860
Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Increasing incidence of late s ...... on for non-Hodgkin's lymphoma.
@ast
Increasing incidence of late s ...... on for non-Hodgkin's lymphoma.
@en
type
label
Increasing incidence of late s ...... on for non-Hodgkin's lymphoma.
@ast
Increasing incidence of late s ...... on for non-Hodgkin's lymphoma.
@en
prefLabel
Increasing incidence of late s ...... on for non-Hodgkin's lymphoma.
@ast
Increasing incidence of late s ...... on for non-Hodgkin's lymphoma.
@en
P2093
P356
P1476
Increasing incidence of late s ...... on for non-Hodgkin's lymphoma.
@en
P2093
Arnold S Freedman
Donna Neuberg
Heather Yeckes
Jennifer R Brown
Jonathan W Friedberg
Lee M Nadler
P304
P356
10.1200/JCO.2005.05.158
P407
P577
2005-03-07T00:00:00Z